Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

Jianming He, Heather Berringer, Bart Heeg, Tobias Kampfenkel, Harikumaran R. Dwarakanathan, Stephen Johnston, João Mendes, Annette Lam, Sacheeta Bathija, Eric Mackay

Blood (2021) 138 (Supplement 1): 4083.

https://doi.org/10.1182/blood-2021-146044

Published: 2021

Journal Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric M. Ammann, Annette Lam, Mark Wildgust, Shaji Kumar

Blood (2021) 138 (Supplement 1): 118.

https://doi.org/10.1182/blood-2021-144914

Published: 2021

Journal Articles

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Eric M. Ammann, PhD, Annette Lam, MSc, Wenze Tang, MPH, Tobias Kampfenkel, MD, Mohit Sharma, Charlene Lee, MSc, Shuchita Kaila, PhD, Alex Z. Fu, PhD, Kathleen Gray, PhD, Jianming He, PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-139882

Published: 2020

Journal Articles

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

Vania T.M. Hungria, MD PhD, Deborah M. Martinez-Banos, Maria-Victoria Mateos, Meletios A. Dimopoulos, MD, Michele Cavo, Bart Heeg, PhD, Annette Lam, Gerardo Machnicki, Jianming He, PhD, Mariana Fernandez

Blood (2019) 134 (Supplement_1): 2143.

https://doi.org/10.1182/blood-2019-123557

Published: 2019

Journal Articles

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Thierry Facon, MD, Jesús San-Miguel, Saad Z. Usmani, MD, Meletios A. Dimopoulos, MD, Shaji K. Kumar, MD, Maria-Victoria Mateos, Michele Cavo, Bart Heeg, PhD, Sophie Van Beekhuizen, MSc, Marta Pisini, MBA, Sandhya Nair, Annette Lam, BSc, MSc, Mary Slavcev, Jianming He, PhD

Blood (2019) 134 (Supplement_1): 2144.

https://doi.org/10.1182/blood-2019-123561

Published: 2019

Journal Articles

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Michele Cavo, MD, Meletios A Dimopoulos, MD, Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Andrzej Jakubowiak, MD PhD, William Deraedt, Annette Lam, Tobias Kampfenkel, MD, Ming Qi, MD PhD, Jianming He, PhD

Blood (2018) 132 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2018-99-113128

Published: 2018

Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD

Blood (2018) 132 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2018-99-113157

Published: 2018

Journal Articles

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Hervé Avet-Loiseau, MD PhD, Jianming He, PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Sourish Saha, Christopher Chiu, PhD, Sarah Cote, Annette Lam

Blood (2018) 132 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2018-99-113571

Published: 2018

Journal Articles

Patient-Reported Outcomes Validation of the FACT-Leu in Acute Myeloid Leukemia: A Review of Baseline Characteristics in AML2002

Jianming He, PhD, Renee Pierson, MBA, Christina Loefgren, MD PhD, David Cella, PhD

Blood (2018) 132 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2018-99-114635

Published: 2018

Journal Articles

Patient-Reported Disease Burden in the Elderly Patients with Acute Myeloid Leukemia

Renee Pierson, MBA, Jianming He, PhD, Liang Xiu, PhD, Sepideh Nemat, MD PhD, Christina Loefgren, MD PhD, Xavier Thomas, MD

Blood (2017) 130 (Supplement 1): 2182.

https://doi.org/10.1182/blood.V130.Suppl_1.2182.2182

Published: 2017

Journal Articles

Relationship between Complete Remission and Overall Survival in Acute Myeloid Leukemia: A Report from Daco-016 and Daco-017

Jianming He, PhD, Margaret T. Doyle, BSPharm, MSc, Liang Xiu, PhD, Sepideh Nemat, MD PhD, Christina Loefgren, MD PhD, Xavier Thomas, MD

Blood (2017) 130 (Supplement 1): 2589.

https://doi.org/10.1182/blood.V130.Suppl_1.2589.2589

Published: 2017

Journal Articles

Transfusion Burden and Outcomes in Patients with Low- or Unspecified-Grade Myelodysplastic Syndromes Treated with Erythropoiesis-Stimulating Agents: Analysis of a United States Commercial Claims Database

Maneesha Mehra, Ravi Potluri, Jianming He, Aleksandra Rizo, Suneel Mundle, Jacqueline Bussolari

Blood (2016) 128 (22): 5974.

https://doi.org/10.1182/blood.V128.22.5974.5974

Published: 2016

Journal Articles

Characterization of Disease, Treatment Patterns, and Outcomes of Patients with Myelofibrosis: Analysis of 2 United States Commercial Claims Databases

Maneesha Mehra, Ravi Potluri, Jianming He, Grace Wang, Suneel Mundle, Jacqueline Bussolari

Blood (2016) 128 (22): 4769.

https://doi.org/10.1182/blood.V128.22.4769.4769

Published: 2016

Journal Articles

Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial

Donald Robinson, Jr., Robert Z. Orlowski, MD PhD, Jianming He, PhD, Annette Lam, Ning Zhao, Andrew Z Cakana, MB, ChB, MD Sc, FRCPath

Blood (2015) 126 (23): 875.

https://doi.org/10.1182/blood.V126.23.875.875

Published: 2015

Journal Articles

Patient-Relevant Experiences and Impacts of Acute Myeloid Leukemia: Evidence from Online Social Networks-Based Qualitative Research

Shruti Kusumgar, MBA, Kevin Johnson, Monica Belford, Avinash Desai, MD, Jianming He, PhD

Blood (2015) 126 (23): 4523.

https://doi.org/10.1182/blood.V126.23.4523.4523

Published: 2015

Journal Articles

Superior Restoration of Health with Siltuximab Among Multicentric Castleman’s Disease Patients When Measured By SF-36

Frits van Rhee, MD PhD, Corey Casper, MD, Margaret K Vernon, PhD, Dylan Trundell, MSc, Don Robinson, MSPH, Jianming He, PhD, Jessica Vermeulen, MD PhD, Helgi van de Velde, MD PhD, Raymond S Wong, MD

Blood (2014) 124 (21): 4469.

https://doi.org/10.1182/blood.V124.21.4469.4469

Published: 2014

NARROW

Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Patient-Reported Outcomes Validation of the FACT-Leu in Acute Myeloid Leukemia: A Review of Baseline Characteristics in AML2002

Patient-Reported Disease Burden in the Elderly Patients with Acute Myeloid Leukemia

Relationship between Complete Remission and Overall Survival in Acute Myeloid Leukemia: A Report from Daco-016 and Daco-017

Transfusion Burden and Outcomes in Patients with Low- or Unspecified-Grade Myelodysplastic Syndromes Treated with Erythropoiesis-Stimulating Agents: Analysis of a United States Commercial Claims Database

Characterization of Disease, Treatment Patterns, and Outcomes of Patients with Myelofibrosis: Analysis of 2 United States Commercial Claims Databases

Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial

Patient-Relevant Experiences and Impacts of Acute Myeloid Leukemia: Evidence from Online Social Networks-Based Qualitative Research

Superior Restoration of Health with Siltuximab Among Multicentric Castleman’s Disease Patients When Measured By SF-36

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only